reports
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of a non-qualified stock option to purchase 108,000 shares of Class A common stock and restricted stock units (RSUs) for 53,000 shares of Class A common stock to Jason S. Carter, Vera’s new Chief Legal Officer, under Vera’s 2024 Inducement Plan. The Compensation Committee approved the a...
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately. “We are excited to have Jason join our growing team. With our pivotal ORIGIN 3 trial of atacicept in IgAN on track to announce topline results in the second quarter of 2025 and...
Erasca Reports Third Quarter 2024 Business Updates and Financial Resul...
Erasca Reports Third Quarter 2024 Business Updates and Financial Results Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025 Strong execution across potentially best-in-class RAS targeting franchise; planned IND submissions on track Robust balance sheet with cash, cash equivalents, and marketable securities of $463 million as of September 30, 2024, is expected to fund operations into H1 2027 SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eras...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule ...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Brisbane, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 4, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 54,050 shares of Class A common stock and restricted stock units (RSUs) for 27,025 shares of Class A common stock to seven new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in ...
Vera Therapeutics Partners with University of Michigan on the NEPTUNE ...
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study Participants with nephrotic syndrome in NEPTUNE Match will receive information about the PIONEER study and other clinical trials based on their individual disease characteristics;PIONEER study expands the investigation of atacicept into multiple autoimmune glomerular diseases, supported by the disease-modifying potential of BAFF/APRIL dual inhibition; BRISBANE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company fo...
Vera Therapeutics to Participate at Upcoming Investor Conferences
Vera Therapeutics to Participate at Upcoming Investor Conferences BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: Guggenheim Securities Healthcare Innovation ConferenceFormat: Fireside Chat and 1x1sWebcast: Date:...
Vera Therapeutics to Participate at Upcoming Investor Conferences
Vera Therapeutics to Participate at Upcoming Investor Conferences BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences. Investor Conference Details: Guggenheim Securities Healthcare Innovation ConferenceFormat: Fireside Chat and 1x1sWebcast: Date: Wednesd...
- Wedbush Research
GEO GEO GROUP INC. (THE)
XENE XENON PHARMACEUTICALS INC
WING WINGSTOP INC.
TSLA TESLA INC
SAGE SAGE THERAPEUTICS INC.
RNG RINGCENTRAL INC. CLASS A
PZZA PAPA JOHN'S INTERNATIONAL INC.
NBIX NEUROCRINE BIOSCIENCES INC.
LOW LOWE'S COMPANIES INC.
KURA KURA ONCOLOGY INC.
HD HOME DEPOT INC.
GOOGL ALPHABET INC. CLASS A
FTNT FORTINET INC.
EXPE EXPEDIA GROUP INC.
CXW CORECIVIC INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
PTGX PROTAGONIST THERAPEUTICS
RDFN REDFIN CORPORATION
AMZN AMAZON.COM INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
BKNG BOOKING HOLDINGS INC.
HEAR TURTLE BEACH CORP.
RH RESTORATION HARDWARE INC.
PINS PINTEREST INC. CLASS A
GOSS GOSSAMER BIO
STOK STOKE THERAPEUTICS
DT DYNATRACE INC.
DDOG DATADOG INC CLASS A
APRE APREA THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
U UNITY SOFTWARE
RZLT REZOLUTE
ABNB AIRBNB INC. CLASS A
PLTR PALANTIR TECHNOLOGIES
VOR VOR BIOPHARMA
BUR BURFORD CAPITAL
CGEM CULLINAN ONCOLOGY INC
UPST UPSTART HOLDINGS
LBPH LONGBOARD PHARMACEUTICALS
VERA VERA THERAPEUTICS INC
TTD THE TRADE DESK
GLUE INC.
ARHS MONTE ROSA THERAPEUTICS INC
CCSI ARHAUS INC
RIVN CONSENSUS CLOUD SOLUTIONS INC
VIGL RIVIAN AUTOMOTIVE INC
PEPG VIGIL NEUROSCIENCE INC
TOST PEPGEN INC
EWTX TOAST INC
GETY EDGEWISE THERAPEUTICS INC
SKLZ GETTY IMAGES HOLDINGS INC
DNTH SKILLZ INC
CRBP DIANTHUS THERAPEUTICS INC
SYRE CORBUS PHARMACEUTICALS HOLDINGS INC.
SPYRE THERAPEUTICS INC.
- Dylan Shindler
- Laura Chico
Vera Therapeutics Provides Business Update and Reports Third Quarter 2...
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results Presented positive 96-week long-term eGFR stabilization data from ORIGIN Ph 2b clinical trial of atacicept in IgAN in a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024 with simultaneous peer-reviewed publication in the Journal of the American Society of Nephrology (JASN)Completed enrollment of the primary endpoint cohort in the pivotal Phase 3 ORIGIN 3 trial of atacicept in IgAN; topline data expected in Q2 2025Announced expanded atacicept development prog...
Erasca to Present at Upcoming Investor Conferences
Erasca to Present at Upcoming Investor Conferences SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences and will also participate in one-on-one investor meetings. Guggenheim Securities Healthcare Innovation Conference (November 11 – 13, 2024)Location: InterContinental Hotel, Boston, MAFormat: Fireside Chat Date a...
Vera Therapeutics Announces Pricing of Public Offering of Class A Comm...
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock BRISBANE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced the pricing of an underwritten public offering of 7,142,858 shares of its Class A common stock at a price to the public of $42.00 per share. The gross proceeds to Vera from the offering, before deducting underwriting discounts and commissions and estima...
Vera Therapeutics Announces Proposed Public Offering of Class A Common...
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock BRISBANE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $300.0 million of shares of its Class A common stock. All of the shares are being offered by Vera. In connection with the proposed offering, Vera expects to...
- Wedbush Research
GEO GEO GROUP INC. (THE)
UBI UBISOFT ENTERTAINMENT SA
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
CXW CORECIVIC INC.
CPT CAMDEN PROPERTY TRUST
BPMC BLUEPRINT MEDICINES CORP.
BIIB BIOGEN INC.
ARDX ARDELYX INC
HST HOST HOTELS & RESORTS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
ARGX ARGENX ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
KNSA KINIKSA PHARMACEUTICALS
ARVN ARVINAS HOLDING
SAFE SAFEHOLD INC.
SMCI SUPER MICRO COMPUTER
IDYA INC.
TVTX IDEAYA BIOSCIENCES
RBLX TRAVERE THERAPEUTICS INC
DAWN ROBLOX
TNGX DAY ONE BIOPHARMACEUTICALS INC
STX TANGO THERAPEUTICS
VERA INC
SEAGATE TECHNOLOGY HLDGS PLC
VERA THERAPEUTICS INC
- Laura Chico
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase...
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 Long-term improvements observed in the quartet of findings defining disease modification supports atacicept’s potential to prevent kidney failure in patients with IgAN;Long-term results from the ORIGIN Phase 2b study were simultaneously published in the Journal of the American Society of Nephrology;Company will host an investor call and webcast on Monday October 28 at 8:00 AM ET BRISBANE, Calif., O...
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Fra...
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise Positive preliminary Phase 1b SEACRAFT-1 data for naporafenib plus trametinib reinforce therapeutic potential in NRASm melanoma and further support ongoing Phase 3 SEACRAFT-2 trial SEACRAFT-2 has potential for approval based on alignment with US and European regulatory agencies on path for tissue-specific indication in melanoma; Stage 1 randomized data expected in 2025 Rapid progress across RAS targeting franchise; planned IND submissions remain on track Erasca to host investor event today at 8:30 AM Eastern Tim...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
TDS TELEPHONE AND DATA SYSTEMS INC.
JBLU JETBLUE AIRWAYS CORPORATION
MDU MDU RESOURCES GROUP INC
CMA COMERICA INCORPORATED
USM UNITED STATES CELLULAR CORP
VALU VALUE LINE INC.
CIA CITIZENS INC. CL A
AIRG AIRGAIN
LW LAMB WESTON HOLDINGS INC.
ROKU ROKU INC. CLASS A
RDVT RED VIOLET
EAT AMREST HOLDINGS SE
NEON NEONODE INC.
PTON PELOTON INTERACTIVE INC. CLASS A
CRMD CORMEDIX INC.
PLRX PLIANT THERAPEUTICS
RNA AVIDITY BIOSCIENCES
ALKT ALKAMI TECHNOLOGY INC
ULCC FRONTIER GROUP HLDGS INC
RELY REMITLY GLOBAL INC
SNCY SUN COUNTRY AIRLINES HLDGS INC
NN NEXTNAV INC
OPFI OPPFI INC
AURA AURA BIOSCIENCES INC
TYRA TYRA BIOSCIENCES INC
MLYS MINERALYS THERAPEUTICS INC
ELVN IMARA INC
SLG SL GREEN REALTY CORP.
WGS GENEDX HOLDINGS CORP.
LXEO LEXEO THERAPEUTICS INC
GDLC GRAYSCALE DIGITAL LARGE CAP FD COM
LB LANDBRIDGE COMPANY LLC
FOA FINANCE OF AMERICA COMPANIES INC.
TECX TD GLOBAL TECHNOLOGY LEADERS CAD HEDGED INDEX ETF
RDDT REDDIT INC
- David Nierengarten
- Dennis Pak
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Bull Trap Still Brewing? The S&P 500 (SPX) continues to hold below 5783, which is the upper-end of an important target/resistance area (5670-5783) we have discussed since our 8/13/24 Compass, just after the SPX hit our 5100-5191 "expected pullback zone." 5670 was the prior all-time high set in July, while 5783 is 2% above 5670. The current "breakout" above 5670 is an extraordinarily weak one, which usually suggests a false breakout/bull trap is brewing; the SPX has spent nearly three weeks abov...
EME EMCOR GROUP
WLDN WILLDAN GROUP
TRN TRINITY INDUSTRIES INC.
TPC TUTOR PERINI CORPORATION
STRL STERLING CONSTRUCTION COMPANY INC.
PWR QUANTA SERVICES INC.
NWPX NORTHWEST PIPE CO.
MTZ MASTEC INC.
GVA GRANITE CONSTRUCTION INCORPORATED
DY DYCOM INDUSTRIES INC.
BWXT BWX TECHNOLOGIES INC.
FLR FLUOR CORPORATION
GLDD GREAT LAKES DREDGE & DOCK CORPORATION
KBR KBR INC.
PRIM PRIMORIS SERVICES CORPORATION
AGX ARGAN INC.
WAB WESTINGHOUSE AIR BRAKE TECHNOLOGIES CORPORATION
ARCAY ARCADIS N.V.
ROAD CONSTRUCTION PARTNERS
BV BRIGHTVIEW HOLDINGS
BW BABCOCK & WILCOX ENTERPRISES
IESC IES HOLDINGS INC.
J JACOBS SOLUTIONS INC.
TISI TEAM INC.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.